The Hedgehog (Hh) family of secreted proteins is involved in a number of developmental processes as well as in cancer. Genetic and biochemical data suggest that the Sonic hedgehog (Shh) receptor is composed of at least two proteins: the tumor suppressor protein Patched (Ptc) and the seven-transmembrane protein Smoothened (Smo). 
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Results

Background
Hedgehog (Hh) is a secreted protein originally identified in Drosophila as having a role in segment polarity, mutants being characterized by loss of pattern and polarity of embryonic segments [1] . Seven Hh homologues have been isolated from different vertebrate species and shown to play important roles during development (reviewed in [2] ). The best characterized of these is Sonic hedgehog (Shh) [3] [4] [5] , the activity of which regulates dorso-ventral patterning of the neural tube (reviewed in [6] ) and the somites (reviewed in [7] ), antero-posterior patterning of the limb buds [8] , and morphogenesis of the hindgut [9] .
The Smoothened (Smo) gene was also first identified in Drosophila through a segment polarity mutant and its function appears to be required for Hh signaling [10, 11] . The subsequent cloning and analysis of Smo showed it to encode a seven-transmembrane protein with a topology reminiscent of the G-protein-coupled receptor (GPCR) superfamily. Interestingly, Smo is most homologous to the Frizzled (Fz) family of serpentine proteins. Biochemical characterization of vertebrate homologues of Smo demonstrated, however, that despite Smo being an activator of the Hh pathway and sharing homology with GPCRs, Smo does not bind Shh [12] .
Patched (Ptc), another segment polarity gene encoding a twelve-transmembrane protein, was also a candidate receptor for Hh [13, 14] . In contrast to Smo, Ptc represses transcription of Hh target genes [15] [16] [17] . Vertebrate homologues of Ptc bind Shh with high affinity [12, 18] , providing biochemical evidence that Ptc is the Shh receptor. Additional experiments indicated that Smo can be coimmunoprecipitated with Ptc and can be found in a ternary complex with Ptc and Shh, suggesting the existence of a multicomponent receptor for Shh [12] . Mutations in human Ptc have been implicated in the basal cell nevus syndrome, a dominant autosomal condition characterized by a complex set of developmental defects and high incidence of basal cell carcinomas (BCCs) [19, 20] . In the BCCs of basal cell nevus syndrome patients, as well as in at least one-third of sporadic BCCs, both alleles of Ptc are lost or mutated, suggesting that Ptc is a tumor suppressor [21] and that, in the absence of Ptc, unregulated Smo signaling can trigger cell proliferation in the skin. Consistent with the multicomponent model of the Shh receptor, activating Smo mutations have been identified in sporadic BCCs of patients who are wild-type for Ptc. Ectopic expression of the mutant Smo proteins in transgenic mice leads to skin abnormalities resembling BCCs, supporting an oncogenic role for Smo in this syndrome [22] .
Gli1, a member of the Gli family of zinc-finger transcription factors [23, 24] which includes Drosophila Cubitus interruptus (Ci), has been identified as a candidate downstream mediator of the Shh response [25] [26] [27] [28] [29] . Gli1 is upregulated in response to Shh [30, 31] and was found to be consistently upregulated in BCCs, indicating activation of the Shh pathway in this type of tumor [32] .
Despite the recent identification of Ptc as the Shh receptor and the cloning of a number of components of the Hh signal transduction pathway in Drosophila (reviewed in [33] 
Results
Activation of a Gli-binding-site reporter in response to Shh and Smo
To study Shh signaling and the role of the Ptc-Smo receptor complex, we used the mouse embryonic fibroblast cell line C3H10T1/2, which undergoes osteoblast differentiation in response to Shh as measured by alkaline phosphatase staining in Shh-stimulated cells [34] (Figure 1a) . Transfection of human Gli1 recapitulates the effect of Shh, indicating that activation of Gli1 mediates the effect of Shh in these cells (Figure 1a ). To monitor Gli activation, we generated a reporter construct consisting of nine copies of a Gli-binding site (Gli-BS) present in the mouse HNF-3β enhancer, upstream of the herpes simplex virus (HSV) thymidine kinase (TK) minimal promoter and the luciferase gene. To determine the specificity of the response, we also constructed a reporter plasmid carrying a mutated version of the Gli-binding site (mGli-BS) that is unable to bind Gli and does not respond to Shh [35] . Cotransfection into C3H10T1/2 cells of the Gli-BS reporter with a vector encoding full-length mouse Shh was able to induce luciferase activity (Figure 1b ) whereas transfection of Shh with the mGli-BS plasmid resulted in background levels of induction, indicating that the response to Shh was dependent on the presence of wild-type Glibinding sites. Similar results were obtained by stimulating cells transfected with the Gli-BS reporter with recombinant amino-terminal Shh (N-Shh) (data not shown). As expected, strong induction of luciferase activity was observed when the Gli-BS reporter was cotransfected with a Gli1 expression plasmid (Figure 1b ).
When human Smo was cotransfected into C3H10T1/2 cells with the Gli-BS reporter, it induced luciferase activity in a wild-type Gli-BS-dependent manner to an even greater extent than Shh (Figure 1b) . Two other seventransmembrane proteins, the human interleukin-8 receptor (data not shown) and rat Fz-5 (Figures 2a,3a) , were unable to induce a response, indicating that Smo is a specific activator of the Shh pathway and that the response cannot be triggered by unrelated seven-transmembrane proteins. Likewise, transfection of Ptc did not induce luciferase activity (Figure 1b) , demonstrating that ectopic expression of Ptc cannot activate the Shh signaling pathway.
Different domains of Smo are required for signaling and Ptc interaction
In order to map the domain(s) of Smo required for signaling, we generated several Smo deletion mutants as well as chimeric receptors between human Smo and one of its closest known homologues, Fz-5 ( Figure 2 ). Smo deletion constructs lacking either the amino-terminal extracellular domain (ECD), or the carboxy-terminal cytoplasmic tail, were tested for their ability to induce the reporter plasmid ( Figure 1c ). Both constructs triggered activation of the reporter, suggesting that these two domains are not required for the signaling activity of Smo.
To generate Smo-Fz chimeric receptors, we replaced the amino-terminal region of Smo with the corresponding region of rat Fz-5, starting from the ECD and including the first two TM domains (chimera 1), or the first four TM domains (chimera 2). We also constructed the reverse chimeras (chimeras 3 and 4) by replacing the carboxy-terminal region of Smo with the corresponding one from Fz-5 ( Figure 2 ). These four chimeric receptors were tested for their ability to induce transcription from the Gli-BS reporter ( Figure 3a ). Chimeras 1 and 2 were able to trigger transcription of luciferase, whereas chimeras 3 and 4 failed to activate transcription of the reporter gene although they expressed at least as well as the first two chimeras ( Figure 3d ). Together, these data demonstrate that the region of Smo required to activate the Gli reporter spans the i3 loop (including the adjacent fifth and sixth TM domains) and the seventh TM domain (the carboxy-terminal cytoplasmic tail not being required). Expression of additional chimeric receptors containing only the i3 loop without the seventh TM domain of Smo in Fz-5 (Fz-i3Smo), or the reverse chimera in Smo-M2 (M2-i3Fz), indicate that the presence of only one of these two domains can lead to a receptor capable of Gli activation ( Figure 3b ). It would be interesting to determine the signaling specificity of these chimeric receptors, because similar swaps between muscarinic cholinergic and β-adrenergic receptors leads to promiscuous signaling [36] .
To determine which region(s) of Smo interact with Ptc, we carried out coimmunoprecipitation experiments with Ptc and the different Smo chimeras (Figure 3c ,d). Smo, Fz and the various chimeras run on SDS-polyacrylamide gels as multimers, even under reducing conditions [12] . Smo and chimeras 3 and 4 showed the strongest interaction with Ptc. Chimeras 1 and 2 had a much lower affinity for Ptc, and Fz-5 did not form a physical complex with Ptc. These data suggest that (in contrast to Gli reporter activation, which requires motifs in the carboxy-terminal half of Smo) the Ptc-Smo interaction occurs mainly through the amino-terminal portion of Smo, with a less important contribution provided by the rest of the molecule.
Ptc can block signaling by Smo
Ptc is a downstream target of Hh in both Drosophila [37] and vertebrates [38] and its upregulation constitutes a way to limit the response to Hh [39] . To analyze whether Ptc is able to block Smo signaling, we cotransfected Ptc from a green fluorescent protein (GFP) expression vector (Ptc-GFP) with limiting amounts of Smo which was epitope-tagged at its amino terminus (gD-Smo) [22] . [22] . When tested in the luciferase assay for Gli reporter activation, both Smo-M1 and Smo-M2 were able to induce luciferase activity ( Figure 1c ). When coexpressed with Ptc, however, Smo-M1 and Smo-M2 were still able to induce luciferase activity, indicating that signaling by these mutants is not repressed by Ptc (Figure 4b ). Because the Smo sequence predicts it to be a member of the superfamily of GPCRs and Gli reporter activation is mediated by domains typically involved in coupling to G proteins, we tested whether transduction of the Shh signal involved second messengers typically linked to G-protein activation. In these experiments, we examined the response either in wild-type C3H10T1/2 cells or in cells cotransfected with Ptc and Smo. No increase in the level of intracellular cAMP was detected when wild-type or transfected cells were stimulated with recombinant NShh. Similarly, no significant inhibition of forskolin-stimulated accumulation of cAMP was detected in response to N-Shh (Figure 5a,b) . We also measured the intracellular calcium ion (Ca 2+ ) concentration in response to N-Shh as a readout for generation of inositol-1,4,5-trisphosphate. In contrast to the muscarinic acetylcholine receptor agonist carbachol and the Ca 2+ ionophore ionomycin, no changes were detected after stimulation of cells with various concentrations of N-Shh (Figure 5c,d ). Similar data were obtained by directly measuring the concentration of phosphatidylinositols (data not shown).
Discussion
Smo is the signaling component of the Shh receptor
The Shh receptor represents a novel paradigm and little was known of the mechanism by which it signals upon binding of its ligand. We have shown here that in a reporter assay for Gli activation, 
Domains of Smo implicated in signaling
In well-characterized GPCRs, the i3 loop is the most critical region for interaction with G proteins; the second intracellular (i2) loop and the carboxyl terminus are also involved, but to a lesser extent (reviewed in [42] ). Chimeric receptors containing the i2 and i3 loops and the carboxyl terminus of Smo, or just the i3 loop and the carboxyl terminus, were able to signal in our assay. Nevertheless, chimeric receptors in which only the i3 loop of Smo was replaced in Fz-5 or in which the i3 loop of Fz was introduced in Smo-M2 were both active. Interestingly, similar experiments using chimeras constructed from receptors with different G-protein-coupling specificities lead to promiscuous G-protein coupling [36] . It would be interesting, therefore, Protein kinase A (PKA) is an antagonist of the Hh pathway in both Drosophila [43, 44] and vertebrate cells [45] . PKA could potentially impinge on the Hh pathway at several levels: the carboxyl terminus of Smo contains PKA phosphorylation sites which might be important in regulating the desensitization/turning over of the protein [10, 11] ; in Drosophila, PKA controls the processing of Ci from an activator form to a repressor form [46] ; and finally, the cAMP responsive element binding protein (CREB) binding protein (CBP), a cofactor for Ci, is activated by PKA (reviewed in [47] ), suggesting that competition for CBP binding between Ci and CREB might regulate the activation of Hh target genes [48] . Although it is tempting to speculate that Smo couples to a trimeric G protein and controls the activity of PKA through the levels of cAMP, we have not been able to detect any change in intracellular cAMP or Ca 2+ (or phosphatidylinositol) levels in C3H10T1/2 cells stimulated with N-Shh. Consistent with these findings, it was reported that Hh can signal normally in cells carrying an altered form of PKA that is insensitive to cAMP concentrations [49] . A possible interpretation of these results would be that the signal is transduced either through the Gβγ subunits of a trimeric G protein or through a novel mechanism.
Ptc blocks signaling by Smo
Vertebrate Ptc binds Shh with high affinity and forms a complex with Smo [12] . Here, we demonstrate that coexpression of Ptc can block Smo signaling, and that addition of recombinant N-Shh is sufficient to restore activation of the Gli reporter. These data provide functional evidence for a model in which Ptc is the ligand-binding subunit and with Ptc. As the Smo construct lacking the amino-terminal ECD was coimmunoprecipitated with Ptc at similar levels to full-length Smo (data not shown), we concluded that the region spanning residues 218 (the beginning of the aminoterminal ECD truncation construct) to 295 (the junction between Fz and Smo in chimera 1) might contain the main Ptc-Smo interaction site(s). Although chimeras 1 and 2 have a lower affinity for Ptc, they are capable of signaling as well as wild-type Smo and are not blocked by coexpression of Ptc, indicating that different regions of Smo are responsible for Ptc interaction and activation of downstream signaling. Point mutations in the amino terminus might not be sufficient to disrupt the Ptc-Smo interface, however, and we did not identify such mutations in a screen of 47 sporadic BCCs [22] .
The two mutant Smo molecules that were identified in sporadic BCCs, Smo-M1 and Smo-M2, are capable of activating Gli as measured by our reporter assay and bind normally to Ptc [22] , as predicted by the chimeric receptors analyzed above. When Ptc was coexpressed with these mutant Smo proteins, though, activation of the Gli reporter gene could not be blocked. These data provide evidence that specific mutations in the carboxyl terminus can uncouple Smo signaling from repression by Ptc despite a strong interaction between the two molecules. These mutations may be locking the receptor in a conformation that mimics the active form despite the presence of bound Ptc. Although Smo-M1 is found less frequently and is a less potent oncogene in our hands, its oncogenic activity is more difficult to explain, because a Smo construct lacking the carboxy-terminal cytoplasmic region was still able to fully activate the Gli reporter. The carboxyterminal region of GPCRs plays a role in desensitization of the receptor and carries endocytic signals required for sequestering (reviewed in [50] ). Therefore, mutation in the cytoplasmic tail such as that found in Smo-M1 may affect receptor desensitization or sequestration. Unraveling the mechanisms by which Ptc controls Smo signaling may lead to the development of molecules that are pharmacologically useful for the treatment of BCCs or other pathologies caused by loss of Ptc function.
Conclusions
Our results provide direct functional evidence that Smo is the signaling component of the Shh receptor complex and that its activity can be repressed by Ptc in a ligand-dependent manner. Therefore, Ptc exerts its tumor suppressing activity by controlling Smo signaling and loss of Ptc function leads to unregulated Smo signaling, a common occurrence in BCCs. Alternatively, oncogenic Smo mutations have been identified and are shown here to be insensitive to Ptc repression, although they are still able to form a complex with Ptc. 
Material and methods
Expression constructs and chimeras
Human Smo, Smo-M1 and Smo-M2 were tagged with the gD epitope from HSV [51] at their amino terminus by PCR-based mutagenesis using Pfu DNA polymerase (Stratagene), and cloned into pRK5 under the control of the cytomegalovirus (CMV) promoter. For cotransfection experiments, human Ptc was cloned into a CMV-based expression vector coexpressing the enhanced GFP (Clontech) from a CMV promoter. Human Smo-rat Fz-5 chimeric receptors were generated by PCR using Pfu DNA polymerase (Stratagene). Primers spanning the Smo and Fz-5 regions of each chimera were used to amplify different Smo and Fz-5 fragments, the PCR products were then gel purified and used as template to amplify, with flanking primers, the entire chimeras. A Myc epitope was added to the carboxyl terminus of every chimera. All the constructs were checked by sequencing.
Luciferase assay
The reporter plasmids Gli-BS and mGli-BS were constructed by placing nine copies of a Gli-binding site element present in the mouse HNF-3β enhancer, or a mutated version of it [35] , in front of the HSV TK promoter in the plasmid pGL3-Basic (Promega). C3H10T1/2 cells were seeded into six-well plates at 9 × 10 4 cells/well the day before transfection. Cells were transfected with 1 µg reporter, 1 µg expression plasmid, and 0.0025 µg reference plasmid (pRL-TK, Promega) using lipofectamine (Gibco BRL). Reporter gene activity was determined 48 h after transfection with the Dual-Luciferase Reporter Assay System (Promega). Normalization of transfection efficiencies was carried out using Renilla luciferase activities. All reporter assay experiments were repeated at least three times, and transfections done in duplicates.
Immunoprecipitations
For coimmunoprecipitation experiments COS-1 cells were transiently transfected with the various expression plasmids in 10 cm plates by electroporation. 36 hours after transfection cells were collected and lysed 20 min on ice in 1 ml of 1% NP-40 lysis buffer containing 50 mM Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM PMSF and protease inhibitors (Complete, Boehringer Mannheim). Cell debris were removed by centrifugation at 10,000 rpm and the supernatant precleared for 1 h with 15 µl protein G-Sepharose (Pharmacia). Lysates were immunoprecipitated using anti-FLAG M2 (Kodak) or anti-Myc (9E10) antibodies followed by protein G-Sepharose, and washed three times with lysis buffer, three times with lysis buffer containing 1 M NaCl, and then again three times with lysis buffer. Samples were run on a denaturing 6% SDS-polyacrylamide gel, transferred to a nitrocellulose membrane and probed with antibodies to the Myc epitope followed by a horseradish-peroxidase-conjugated sheep anti-mouse immunoglobulin (Amersham). The blots were developed using the enhanced chemiluminescence detection system (Amersham).
Cytofluorometry combined reporter assay
C3H10T1/2 cells seeded in 15 cm plates were transfected 24 h after plating with 3 µg of gD-Smo, 6 µg of Ptc-GFP or control GFP vector, 8 µg of reporter plasmid, and 0.01 µg pRL-TK. 48 h after transfection 1 × 10 6 cells were labeled for FACS analysis with an anti-gD monoclonal antibody as described previously [52] and gD/GFP double-positive cells were sorted with an Epics Elite cell sorter (Coulter). Equal amounts of double-positive cells were then either directly lysed and processed for luciferase activity, or replated in presence of 50 nM recombinant N-Shh for an additional 14 h and then lysed. A similar protocol was used to sort for Ptc/chimera 1 or 2 double-positive cells, except that cells were cotransfected with 6 µg of Ptc-GFP or control GFP and 2 µg of Smo, chimeras 1 or 2 cloned in a blue fluorescent protein (BFP) expression vector (Smo-BFP, Ch1-BFP and Ch2-BFP). BFP/GFP double-positive cells were sorted and processed for luciferase activity. Luciferase activity was measured with the DualLuciferase Reporter Assay System (Promega), and values were normalized using Renilla luciferase activity. All experiments were repeated at least three times.
cAMP assay
To quantify intracellular cAMP, cells were either directly plated at a density of 1 × 10 5 cells/well the day before the assay, or transfected 24 h before stimulation with 1 µg Ptc and 1 µg Smo in six-well plates. Prior to addition of the ligand, cells were equilibrated for 15 min at 37°C in serum-free medium containing 100 µM isobutylmethylxanthine (Calbiochem). N-Shh (500 nM) was then added in the presence or absence of 5 µM forskolin (Sigma), and incubation was continued for another 10 min. To isolate cAMP, cells were lysed with ice cold 10% TCA, and cell extracts separated by chromatography on Amprep SAX columns (Amersham), according to the manufacturer's instructions. The cAMP concentrations were determined by 125 I scintillation proximity assay (Amersham). Because Current Biology operates a 'Continuous Publication System' for Research Papers, this paper has been published on the internet before being printed. The paper can be accessed from http://biomednet.com/cbiology/cub -for further information, see the explanation on the contents page.
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